Evidence map›Paper›PMID 41568525›Full record

ArticleHaematologica2026

Recombinant von Willebrand Factor (vonicog alfa) reduces platelet inhibition caused by antiplatelet drugs and has potential as an acute haemostatic agent.

Michael J R Desborough, Joanne L Mitchell, Polly Whitworth, Ashifa Al Juwaiser, Tanya Sage, Neline Kriek, Gemma Little, Sakthivel Vaiyapuri, Jonathan M Gibbins, Alexander P Bye

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Michael J R DesboroughDepartment of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK; Radcliffe Department of Medicine, University of Oxford; NHS Blood and Transplant, Oxford.
Joanne L MitchellInstitute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham.
Polly WhitworthDivision of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK; Oxford Cardiovascular Clinical Research Facility (CCRF), John Radcliffe Hospital, Oxford.
Ashifa Al JuwaiserSchool of Pharmacy, University of Reading, Reading.
Tanya SageInstitute for Cardiovascular and Metabolic Research, Harborne Building, University of Reading, Reading.
Neline KriekInstitute for Cardiovascular and Metabolic Research, Harborne Building, University of Reading, Reading.
Gemma LittleInstitute for Cardiovascular and Metabolic Research, Harborne Building, University of Reading, Reading.
Sakthivel VaiyapuriSchool of Pharmacy, University of Reading, Reading.
Jonathan M GibbinsInstitute for Cardiovascular and Metabolic Research, Harborne Building, University of Reading, Reading.
Alexander P ByeSchool of Pharmacy, University of Reading, Reading, UK; Institute for Cardiovascular and Metabolic Research, Harborne Building, University of Reading, Reading. a.bye@reading.ac.uk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID41568525
PMCPMC13317825

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.